BiOptix Announces Partnership with XTAL Biostructures
News Sep 24, 2015
BiOptix has announced that XTAL BioStructures Inc., a pharmaceutical and biotechnology industries service provider, is adding the BiOptix 404pi to its suite of biophysical tools.
XTAL BioStructures is a contract research organization that provides drug discovery and intellectual property development services to the pharmaceutical and biotechnology industries, including high quality protein production, biophysical characterization, X-ray crystallography and with a focus on affinity-based screening techniques.
“This partnership will further XTAL’s dedication to providing high quality research services through the availability of the BiOptix Enhanced Surface Plasmon Resonance (eSPR) technology, an advanced and highly sensitive optical technology,” said Robert K. Suto, Ph.D., president and CSO of XTAL BioStructures.
XTAL is now able to offer customers access to BiOptix’s patented enhanced surface plasmon resonance (e-SPR) technology, which delivers high sensitivity (100 Da) and higher throughput by combining proprietary technology with an advanced, multi-injector fluidics system.
“With the addition of the BiOptix 404pi label-free system to their existing suite of biophysical tools, both companies can now work together to assist those customers who need both biophysical assessment and real-time, label-free interaction analysis to move their drug discovery projects forward,” said Rick Whitcomb, president and CEO of BiOptix.
Kidney Cancer Driver Could Lead to New Treatment StrategyNews
Scientists have uncovered a potential therapeutic target for kidney cancers that have a common genetic change. Scientists have known this genetic change can lead to an overabundance of blood vessels, which help feed nutrients to the tumors. Their latest finding shows a potential new cancer-driving pathway.READ MORE
Targeting Headaches and Tumors with Nano-SubmarinesNews
Scientists have developed a new method to enable miniature drug-filled nanocarriers to dock on to immune cells, which in turn attack tumors. In the future, this may lead to targeted treatment that can largely eliminate damage to healthy tissue.READ MORE
CRISPR Screening Reveals Sickle Cell Disease TargetNews
A key signaling protein, known as heme-regulated inhibitor (HRI), has been identified as a potential therapeutic target for the development of drugs to treat sickle cell disease, using a CRISPR screening approach.READ MORE